<DOC>
	<DOCNO>NCT00134082</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy , cyclophosphamide , work different way stop growth cancer cell either kill cell stop dividing . Vaccines make another person 's cancer cell may help body build effective immune response kill cancer cell . Giving rituximab together chemotherapy vaccine therapy may kill cancer cell PURPOSE : This phase I/II trial study well give rituximab together cyclophosphamide vaccine therapy work treat patient relapse Hodgkin lymphoma .</brief_summary>
	<brief_title>Rituximab Cyclophosphamide Followed Vaccine Therapy Treating Patients With Relapsed Hodgkin Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety tolerability rituximab high-dose cyclophosphamide follow vaccine therapy comprise allogeneic vaccine express Hodgkin 's tumor antigens sargramostim ( GM-CSF ) ( KGEL vaccine ) salvage therapy patient relapse Hodgkin lymphoma . - Determine immunologic response vaccine patient . Secondary - Determine 3-year relapse-free overall survival patient treat regimen . - Determine pattern cellular immune reconstitution patient treat regimen . OUTLINE : This open-label study . Patients receive rituximab IV day -10 -7 day 29 , 36 , 43 , 50 ( week 4-7 ) high-dose ( transplant-dose ) cyclophosphamide IV day -3 0 without stem cell rescue . Patients receive filgrastim ( G-CSF ) subcutaneously daily begin day 6 continue blood count recover . Patients also receive vaccine therapy comprise allogeneic vaccine express Hodgkin 's tumor antigens sargramostim ( GM-CSF ) ( KGEL vaccine ) intradermally day 1 , week 4 , 8 , 12 , 16 , 24 . After completion high-dose cyclophosphamide , patient follow every 3 month 3 year , annually thereafter . PROJECTED ACCRUAL : Approximately 25 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm classical Hodgkin 's lymphoma Relapsed disease achievement least partial response metabolic response recent salvage therapy No primary induction failure , define disease progression within 2 month completion firstline therapy PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 75,000/mm^3 Hepatic Bilirubin ≤ 2.0 mg/dL* NOTE : *Unless due lymphoma Gilbert 's syndrome Renal Creatinine ≤ 2.0 mg/dL Cardiovascular Ejection fraction ≥ 45 % echocardiogram MUGA Pulmonary DLCO ≥ 50 % predict ( correct alveolar volume ) Immunologic No known HIV positivity No active infection require oral IV antibiotic No autoimmune disease require longterm systemic steroid longterm immunosuppressant Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able tolerate highdose therapy No malignancy within past 3 year except basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior bone marrow transplantation Endocrine therapy Not specify Radiotherapy Concurrent radiotherapy disease progression highdose cyclophosphamide allow discretion principal investigator Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
</DOC>